For US healthcare providers
Formulary Coverage
Demonstrated strength of KERENDIA payer coverage1
99%
of Medicare patients
99%
of fee-for-service Medicare patients
88%
of commercially insured patients
Payer coverage for KERENDIA is stronger than ever: nearly 278 million lives covered1
Find local coverage information for your patients
Navigating Prior Authorization
Learn more about navigating the prior authorization (PA) process
Resources to facilitate patient access to KERENDIA
Prior Authorization Guide
Best practices on preparing and submitting a PA, requesting a medical exception, and navigating the appeals process for KERENDIA.
Prior Authorization Checklist
A reference checklist for HCPs and office staff that highlights key prior authorizations criteria for KERENDIA.
Utilize these resources to help guide you through patient access to KERENDIA:
Sample Letters of Medical Necessity
An overview and templated example letter that can help support a patient’s health insurance claim by explaining the clinical rationale to prescribe KERENDIA.
Sample Letters of Medical Exception
An overview and templated example letter to request an exception on your patient’s behalf if their health plan does not cover KERENDIA on their formulary.
Sample Letters of Appeal
An overview and templated example letter to request an appeal when a patient’s insurance plan has denied their KERENDIA PA request.
Sample Tiering Exception Request Letter
An overview and templated example letter to request a tiering exception that may allow the patient to pay a lower copay or coinsurance for their KERENDIA prescription.
Submit a PA online using CoverMyMeds®* and access a full suite of resources available for your practice to help get your patients access to KERENDIA
*CoverMyMeds® is an independent party.
Help your patients fill their KERENDIA prescription with BlinkRx†
BlinkRx provides a streamlined process that can help patients save time and money
For additional support or to submit prescriptions by phone or fax, contact BlinkRx:
Phone: 1 (866) 839-0766
Fax: 1 (866) 585-4361
*CoverMyMeds® is an independent party.
†BlinkRx® is an independent party.
Savings & Support
Resources to support your patients starting KERENDIA
Patient Brochure
Patient Brochure
Utilize these resources to help eligible patients initiate KERENDIA treatment:
30-day Free Trial Voucher
New patients can start on KERENDIA at no cost by using the KERENDIA Free Trial Voucher.*
New patients are eligible for the (30-day) Free Trial Voucher† regardless of insurance.
To get or activate a KERENDIA Free Trial Voucher†:
Call 1-888-537-3634 or
Visit www.KERENDIAsavings.com
Patients may bring the voucher to the pharmacy to redeem their free 30-day supply.
Pay as little as $0* with the KERENDIA Copay Savings Card
Eligible commercial patients pay as little as $0 per month for KERENDIA.*
To activate the KERENDIA Savings Card:
Call 1-888-537-3634 or
Visit www.KERENDIAsavings.com
Once activated, patients may present the card at the pharmacy and the offer will be automatically applied.
Patients who need help paying for their KERENDIA prescription should call 1-888-KERENDIA (537-3634) or visit www.KERENDIAsavings.com to learn more about the affordability options offered by Bayer.
*Terms and Conditions apply. Call 888-KERENDIA or visit www.KERENDIAsavings.com for more information.
†Patients are eligible if they are commercially insured and may pay as little as $0 per month. Benefit limitations apply. Patients who are enrolled in any type of government or reimbursement programs are not eligible. Full terms and conditions apply.
Bayer US Patient Assistance Foundation
If you cannot afford your prescription medication, Bayer may be able to help.
The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Please have your patient contact the program at 1-866-2BUSPAF (228-7723) Monday-Friday, 9:00 AM-6:00 PM EST, or visit the foundation website at www.patientassistance.bayer.us to see if they might qualify for assistance.
Bayer US Patient Assistance Foundation
If you cannot afford your prescription medication, Bayer may be able to help.
The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Please have your patient contact the program at 1-866-2BUSPAF (228-7723) Monday-Friday, 9:00 AM-6:00 PM EST, or visit the foundation website at www.patientassistance.bayer.us to see if they might qualify for assistance.
CKD=chronic kidney disease; EHR=electronic health record; HF LVEF=heart failure with left ventricular ejection fraction; T2D=type 2 diabetes.
Reference:
- Data on file, Bayer. As of October 2025.
- Quick Links
- Resources
- Connect With Us
- Request Samples
INDICATIONS:
KERENDIA (finerenone) is indicated to reduce the risk of:
- sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) (10mg, 20mg tablets)
- cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (HF LVEF) ≥40% (10mg, 20mg, 40mg tablets)
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS:
- Hypersensitivity to any component of this product
- Concomitant use with strong CYP3A4 inhibitors
- Patients with adrenal insufficiency
WARNINGS AND PRECAUTIONS:
Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia
Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5 mEq/L. Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium.
Worsening of Renal Function in Patients with Heart Failure: KERENDIA can cause worsening of renal function in patients with heart failure. Rarely, severe events associated with worsening renal function, including events requiring hospitalization, have been observed
Measure eGFR in all patients before initiation of treatment or with dose titration of KERENDIA and dose accordingly. Initiation of KERENDIA in patients with heart failure and an eGFR <25 mL/min/1.73 m2 is not recommended. Measure eGFR periodically during maintenance treatment with KERENDIA in patients with heart failure. Consider delaying up-titration or interrupting treatment with KERENDIA in patients who develop clinically significant worsening of renal function
MOST COMMON ADVERSE REACTIONS:
- CKD associated with T2D: From the pooled data of FIDELIO-DKD and FIGARO-DKD, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3%), and hyponatremia (1.3% vs 0.7%).
- HF LVEF ≥40%: From FINEARTS-HF, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (9.7% vs 4.2%), hypotension (7.6% vs 4.7%), and hyponatremia (1.9% vs 0.9%). Events related to worsening renal function were reported more frequently in the KERENDIA group (18%) compared with placebo (12%).
DRUG INTERACTIONS:
- Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice.
- Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor, and adjust KERENDIA dosage as appropriate.
- Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers.
- Sensitive CYP2C8 Substrates at KERENDIA 40mg: Monitor patients more frequently for adverse reactions caused by sensitive CYP2C8 substrates if KERENDIA 40mg is co-administered with such substrates, since minimal concentration changes may lead to serious adverse reactions.
USE IN SPECIFIC POPULATIONS:
- Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment.
- Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B).
Please see the full Prescribing Information for KERENDIA.
